Mark Peterson

From a huge 10-restaurant deal to stadium snacks, The ONE Group reveals a capital-efficient playbook for expanding its Benihana and STK brands.

WISeKey's satellite arm, WISeSat, is merging with a SPAC to build a quantum-resilient IoT network, a key step in securing future global communications.

The semiconductor equipment firm will release crucial 2025 and 2026 financial guidance in January, offering a key early test of the industry's momentum.

A relaunched driver's ed franchise is tackling teen safety with a unique local strategy. See how one leader's playbook is empowering franchisees nationwide.

Casey Plummer's appointment signals NDBT's strategic focus on Dallas's property market and a deeper commitment to community-led development initiatives.

Alvotech and Teva's settlement with Regeneron for an Eylea biosimilar paves the way for a 2026 launch, promising increased competition and lower costs.

A new settlement positions a cost-effective alternative to the blockbuster eye drug Eylea for a 2026 U.S. launch, signaling intense market disruption.

Nova Minerals is raising $20M to advance its Estelle Project, a key Alaskan site for gold and the strategically vital mineral antimony amid global supply woes.

A new oral drug, cadisegliatin, enters a major clinical trial in the UAE, aiming to help Type 2 diabetes patients struggling with insulin therapy.

A monumental shift in U.S. drug policy as cannabis is rescheduled. See what this means for Verano, Wall Street, and the future of the industry.

Facing financial headwinds, Celularity lands a critical $12M from a top investor to push its ambitious anti-aging and regenerative therapies forward.

A simple, low-cost heart pill may hold the key to treating Alzheimer's and kidney disease. CardioPharma is now funding research to unlock its potential.

Picard Medical rings the NYSE bell, but its stock's volatile journey reflects the high-stakes gamble on its next-generation artificial heart technology.

Avantor appoints financial heavyweight Simon Dingemans to its board, a strategic move to accelerate its ambitious turnaround amid market pressures.

Asia Pacific Wire & Cable is raising $33.9M via a rights offer to fund its US expansion. Shareholders must now weigh participation against dilution risk.

Etsy is backing its next chapter with a massive share repurchase and a fortified board, as Kruti Patel Goyal prepares to take the CEO reins.

With FDA approval for a pivotal study, Pulse Biosciences' novel nanosecond ablation technology aims to make atrial fibrillation treatment safer and more precise.

Molecular Partners readies for a pivotal presentation at the J.P. Morgan conference, showcasing its next-gen DARPin therapeutics for hard-to-treat cancers.

Completing a key mission 5 months early, Rocket Lab deployed novel DiskSat tech, cementing its role in the U.S. military's agile space strategy.

With FDA & EMA alignment, atebimetinib heads to a Phase 3 trial, offering new hope against deadly pancreatic cancer based on promising early survival data.